OA11740A - Controlled release galantamine composition. - Google Patents

Controlled release galantamine composition. Download PDF

Info

Publication number
OA11740A
OA11740A OA1200100170A OA1200100170A OA11740A OA 11740 A OA11740 A OA 11740A OA 1200100170 A OA1200100170 A OA 1200100170A OA 1200100170 A OA1200100170 A OA 1200100170A OA 11740 A OA11740 A OA 11740A
Authority
OA
OAPI
Prior art keywords
galantamine
formulation according
release
formulation
mpa
Prior art date
Application number
OA1200100170A
Other languages
English (en)
Inventor
John Paul Mcgee
Paul Marie Victor Gilis
Marc Maurice Germain De Weer
Valentin Florent Victor Conde
Herman Johannes Catheri Bruijn
Frederic Anne Rodolf Van Dycke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11740(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of OA11740A publication Critical patent/OA11740A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
OA1200100170A 1998-12-24 1999-12-20 Controlled release galantamine composition. OA11740A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98204447 1998-12-24

Publications (1)

Publication Number Publication Date
OA11740A true OA11740A (en) 2005-05-13

Family

ID=8234559

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100170A OA11740A (en) 1998-12-24 1999-12-20 Controlled release galantamine composition.

Country Status (36)

Country Link
US (3) US7160559B1 (fr)
EP (1) EP1140105B1 (fr)
JP (1) JP2002533396A (fr)
KR (1) KR100437105B1 (fr)
CN (1) CN100370990C (fr)
AP (1) AP1414A (fr)
AR (2) AR022008A1 (fr)
AT (1) ATE252386T1 (fr)
AU (1) AU775914B2 (fr)
BG (1) BG65306B1 (fr)
BR (1) BR9916835A (fr)
CA (1) CA2358062C (fr)
CZ (1) CZ301658B6 (fr)
DE (1) DE69912311T2 (fr)
DK (1) DK1140105T3 (fr)
EA (1) EA004936B1 (fr)
EE (1) EE04996B1 (fr)
ES (1) ES2211215T3 (fr)
HK (1) HK1043062A1 (fr)
HR (1) HRP20010463B1 (fr)
HU (1) HUP0104778A3 (fr)
ID (1) ID29021A (fr)
IL (2) IL143899A0 (fr)
MY (1) MY122411A (fr)
NO (1) NO327988B1 (fr)
NZ (1) NZ511643A (fr)
OA (1) OA11740A (fr)
PL (1) PL349501A1 (fr)
PT (1) PT1140105E (fr)
SI (1) SI1140105T1 (fr)
SK (1) SK287676B6 (fr)
TR (1) TR200101822T2 (fr)
TW (1) TWI262079B (fr)
UA (1) UA79578C2 (fr)
WO (1) WO2000038686A1 (fr)
ZA (1) ZA200105132B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
WO2000038686A1 (fr) 1998-12-24 2000-07-06 Janssen Pharmaceutica N.V. Composition de galantamine a liberation controlee
CA2310950C (fr) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. Posologie de galantamine efficace qui reduit les effets secondaires
CA2310926C (fr) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. Utilisation de la galantamine pour le traitement du comportement neuropsychiatrique associe a la maladie d'alzheimer
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
WO2003032914A2 (fr) * 2001-10-17 2003-04-24 Eisai Co., Ltd. Procedes de traitement de la consommation abusive de substances psychoactives a l'aide d'inhibiteurs de la cholinesterase
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
ES2285233T3 (es) 2002-12-20 2007-11-16 Niconovum Ab Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
US7250258B2 (en) 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
EP2340813A1 (fr) * 2003-12-31 2011-07-06 Actavis Group PTC ehf. Formes galeniques solides a base de galantamine
US20050142193A1 (en) * 2003-12-31 2005-06-30 Lijuan Tang Galantamine formulations
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
GB0408308D0 (en) * 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
AU2005320547B2 (en) * 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
AU2006241771B2 (en) * 2005-04-28 2010-09-09 Eisai R & D Management Co., Ltd. Composition containing anti-dementia drug
US20090087488A1 (en) * 2005-09-05 2009-04-02 Rajan Kumar Verma Galantamine-containing controlled release oral dosage forms, processes for the preparation thereof and use of the manufacture of a medicament
US20070092568A1 (en) * 2005-10-10 2007-04-26 Gore Subhash P Galantamine compositions
WO2007104573A2 (fr) 2006-03-16 2007-09-20 Niconovum Ab Composition améliorée de tabac à priser
EP2010158B1 (fr) * 2006-04-26 2016-02-17 Alphapharm Pty Ltd. Formulations à libération contrôlée qui comprennent une ou plusieurs unités discrètes non enrobées et une matrice à libération retardée
WO2008062426A2 (fr) * 2006-08-02 2008-05-29 Emcure Pharmaceuticals Limited Formulation de dérivés de benzazépine
US7955622B2 (en) 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
DE102006056697A1 (de) * 2006-11-30 2008-06-05 Ratiopharm Gmbh Galanthamin-haltiges Arzneimittel mit kontrollierter Freisetzung
SI2120878T1 (sl) * 2007-02-09 2014-12-31 Alphapharm Pty Ltd Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah
KR100782310B1 (ko) 2007-03-22 2007-12-06 현대약품 주식회사 갈란타민 또는 이의 약학적으로 허용 가능한 염을 포함하는약학 조성물
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
WO2009024858A1 (fr) * 2007-08-22 2009-02-26 Aurobindo Pharma Limited Forme posologique à libération contrôlée de galantamine
EP2190419A1 (fr) * 2007-10-05 2010-06-02 KRKA, D.D., Novo Mesto Système matriciel multiparticulaire contenant de la galantamine
EP2044933A1 (fr) * 2007-10-05 2009-04-08 KRKA, D.D., Novo Mesto Système de matrice à multi-particules contenant de la galantamine
CA2615137A1 (fr) * 2007-12-17 2009-06-17 Pharmascience Inc. Dispositif therapeutique monocouche a liberation controlee
EP2116232B1 (fr) 2008-05-09 2012-02-15 Ratiopharm GmbH Médicament à libération contrôlée comprenant de la galanthamine
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2011064797A2 (fr) 2009-11-26 2011-06-03 Usv Limited Compositions pharmaceutiques à libération contrôlée de galantamine
WO2011151359A1 (fr) 2010-06-02 2011-12-08 Noscira, S.A. Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione
GR1007767B (el) 2011-07-26 2012-11-19 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα παρατεταμενης αποδεσμευσης περιεχον γκαλανταμινη και μεθοδος για την παρασκευη αυτου
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CN109846862A (zh) 2012-10-25 2019-06-07 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
TW201540301A (zh) 2013-08-16 2015-11-01 Takeda Gmbh 以ｐｄｅ４抑制劑治療認知損傷
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
GB201620095D0 (en) * 2016-11-28 2017-01-11 Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And Novel use
US20180333365A1 (en) * 2017-05-19 2018-11-22 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10561612B2 (en) 2017-07-20 2020-02-18 The General Hospital Corporation Powdered formulations of cromolyn sodium and ibuprofen
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
BG67408B1 (bg) 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
AU632458B2 (en) 1987-05-04 1993-01-07 Bonnie Davis Compounds for the treatment of alzheimer's disease
CA1326632C (fr) * 1988-10-26 1994-02-01 Bonnie Davis Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
AT397345B (de) 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
US5336675A (en) 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DK0584185T3 (da) * 1991-05-14 2000-02-07 Ernir Snorrason Behandling af træthedssyndrom med cholinesteraseinhibitorer
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
CN1071570C (zh) * 1993-06-14 2001-09-26 詹森药业有限公司 阿司咪唑和假麻黄碱的缓释薄膜包衣片
DE4319760A1 (de) * 1993-06-15 1994-12-22 Bayer Ag Ipsapiron Arzneimittelzubereitung
WO1995003052A1 (fr) * 1993-07-22 1995-02-02 Warner-Lambert Company Systemes d'administration de medicament a base de tacrine a liberation controlee et procedes de preparation desdits systemes
HU218673B (hu) * 1993-10-07 2000-10-28 Euroceltique S.A. Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
DE4342174C1 (de) * 1993-12-10 1995-05-11 Lohmann Therapie Syst Lts Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
GB9514821D0 (en) 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
JP3833314B2 (ja) * 1995-09-08 2006-10-11 武田薬品工業株式会社 発泡性組成物およびその製造方法
JP3693270B2 (ja) 1995-10-12 2005-09-07 旭化成ケミカルズ株式会社 フィルムコーティング顆粒およびその製造方法
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
JP3134187B2 (ja) 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
CA2272099A1 (fr) * 1996-11-19 1998-05-28 The Procter & Gamble Company Plaquette aide-memoire pour medicaments et procede permettant d'ameliorer ou de faciliter l'observation par un patient de traitements medicamenteux complexes
JPH10231242A (ja) 1997-02-20 1998-09-02 Taiyo Yakuhin Kogyo Kk 持続性ジクロフェナクナトリウム組成物
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TW477702B (en) * 1997-10-23 2002-03-01 Dev Center Biotechnology Controlled release tacrine dosage form
AU1282099A (en) 1997-10-29 1999-05-17 Bonnie M. Davis Method for treatment of disorders of attention
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
WO2000038686A1 (fr) * 1998-12-24 2000-07-06 Janssen Pharmaceutica N.V. Composition de galantamine a liberation controlee
AUPP891299A0 (en) 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
US6273260B1 (en) * 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system

Also Published As

Publication number Publication date
IL143899A (en) 2006-04-10
ES2211215T3 (es) 2004-07-01
DE69912311D1 (de) 2003-11-27
UA79578C2 (en) 2007-07-10
HRP20010463B1 (en) 2011-02-28
EE200100319A (et) 2002-10-15
WO2000038686A1 (fr) 2000-07-06
EP1140105B1 (fr) 2003-10-22
DK1140105T3 (da) 2004-02-23
ID29021A (id) 2001-07-26
US7160559B1 (en) 2007-01-09
EA200100713A1 (ru) 2001-12-24
AU775914B2 (en) 2004-08-19
HUP0104778A2 (hu) 2002-04-29
NO20012857L (no) 2001-06-08
EA004936B1 (ru) 2004-10-28
CA2358062A1 (fr) 2000-07-06
CA2358062C (fr) 2006-12-19
CN100370990C (zh) 2008-02-27
SI1140105T1 (en) 2004-04-30
BG65306B1 (bg) 2008-01-31
TR200101822T2 (tr) 2001-11-21
CN1331596A (zh) 2002-01-16
CZ20012182A3 (cs) 2002-01-16
EP1140105A1 (fr) 2001-10-10
ZA200105132B (en) 2002-06-21
HRP20010463A2 (en) 2002-08-31
AP2001002219A0 (en) 2001-09-30
AU2100600A (en) 2000-07-31
US20060062856A1 (en) 2006-03-23
BG105564A (en) 2002-01-31
NO327988B1 (no) 2009-11-02
BR9916835A (pt) 2001-09-25
AR022008A1 (es) 2002-09-04
SK8862001A3 (en) 2002-02-05
NO20012857D0 (no) 2001-06-08
KR20010075715A (ko) 2001-08-09
KR100437105B1 (ko) 2004-06-23
AR066313A2 (es) 2009-08-12
HK1043062A1 (en) 2002-09-06
MY122411A (en) 2006-04-29
PT1140105E (pt) 2004-03-31
IL143899A0 (en) 2002-04-21
NZ511643A (en) 2003-07-25
TWI262079B (en) 2006-09-21
PL349501A1 (en) 2002-07-29
HUP0104778A3 (en) 2004-05-28
CZ301658B6 (cs) 2010-05-19
JP2002533396A (ja) 2002-10-08
SK287676B6 (sk) 2011-05-06
DE69912311T2 (de) 2004-07-29
ATE252386T1 (de) 2003-11-15
AP1414A (en) 2005-06-13
EE04996B1 (et) 2008-04-15
US20060093671A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
CA2358062C (fr) Composition de galantamine a liberation controlee
CA2655838C (fr) Preparation pharmaceutique pour administration par voie orale avec liberation controlee de substances actives dans l'intestin grele et son procede de fabrication
JP2008507508A (ja) トピラメート徐放性製剤及びその製造方法
JP2011516611A (ja) 弱塩基性薬物を含む組成物及び徐放性剤形
US10391061B2 (en) Delayed release pharmaceutical formulation and methods of making and using same
CN100361660C (zh) 左氧氟沙星缓释微丸、其制备方法及其制药用途
BRPI0615014A2 (pt) composição farmacêutica sólida compreendendo 1-(4-cloroanilino)-4-(4-piridilmetil)ftalazina e um modificador de ph e uso da mesma
WO2009002416A1 (fr) Formulation de chlorhydrate de tamsulosine à libération contrôlée
MX2014007700A (es) Nueva combinacion.
CN100475197C (zh) 口服的可持续释放的药用组合物
WO2003015758A1 (fr) Micro-pastilles a liberation prolongee et procede permettant leur production
MXPA01006529A (en) Controlled release galantamine composition
MXPA99002404A (en) Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2. 2]oct-3-yl)acetonitrile monohydrochloride
SK111595A3 (en) Remedial preparation containing morphine sulfate and preparation method thereof